oradrenaline plus placebo vs noradrenaline plus terlipressin for thetreatment of septic shock
- Conditions
- Septic ShockMedDRA version: 20.0Level: LLTClassification code: 10040089Term: Septicemia Class: 10021881MedDRA version: 23.1Level: PTClassification code: 10040070Term: Septic shock Class: 100000004862Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 152
Adult patients (18 years or older)., Patients with septic shock., Patients with a SOFA index> 4 points. (If the patient is going to be intubated at the time of randomization, take the neurological SOFA score from the medical record), Signature of the informed consent by the patient or his or her legal representative. (Informed consent may be granted by phone if the legal representative is not present at the center at the time of signing, with written re-consent required as soon as possible)
Pregnant or lactating patients, Previous use of terlipressin during your stay in the ICU, Previous use of vasopressin., Known allergy to terlipressin, Pathologies on which terlipressin is clinically indicated: gastrointestinal bleeding due to esophageal-gastric varices, hepatorenal syndrome., Patients diagnosed with unstable acute coronary syndrome., Patients with acute or chronic mesenteric ischemia, Patients with Raynaud's Phenomenon, or vasospastic disease., Patients participating in another intervention clinical trial., Patients with active bleeding., Patients with renal replacement technique at the time of randomization., Patients with some limitation of life support treatment (LLST).
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method